Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer

References

• 1 McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334(1), 1–6 (1996).
  Medline CASGoogle Scholar
• 2 Aebi S, Castiglione M. Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 19(Suppl. 2), ii14–ii16 (2008).
  MedlineGoogle Scholar
• 3 Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21(17), 3194–3200 (2003).
  Medline CASGoogle Scholar
• 4 Lottin S, Adriaenssens E, Dupressoir T et al. Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis 23(11), 1885–1895 (2002).
  Medline CASGoogle Scholar
• 5 Yang F, Bi J, Xue X et al. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J. 279(17), 3159–3165 (2012).
  Medline CASGoogle Scholar
• 6 Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene 26(33), 4877–4881 (2007).
  Medline CASGoogle Scholar
• 7 Zhu Z, Song L, He J, Sun Y, Liu X, Zou X. Ectopic expressed long non-coding RNA H19 contributes to malignant cell behavior of ovarian cancer. Internat. J. Clin. Experiment. Pathol. 8(9), 10082–10091 (2015).
  Medline CASGoogle Scholar
• 8 Petry Cj, Ong Kk, Barratt Bj et al. Common polymorphism in H19 associated with birthweight and cord blood IGF-II levels in humans. BMC Genet. 6(22), doi:10.1186/1471-2156-6-22 (2005).
  MedlineGoogle Scholar
• 9 Ross Ja, Radloff Ga, Sm D. H19 and IGF-2 allele-specific expression in hepatoblastoma. Br. J. Cancer 82(4), 753–756 (2000).
  Medline CASGoogle Scholar
• 10 Van Gurp RJ, Oosterhuis JW, Kalscheuer V, Mariman EC, Looijenga LH. Biallelic expression of the H19 and IGF2 genes in human testicular germ cell tumors. J. Natl Cancer Inst. 86(14), 1070–1075 (1994).
  Medline CASGoogle Scholar
• 11 Gao T, He B, Pan Y et al. H19 DMR methylation correlates to the progression of esophageal squamous cell carcinoma through IGF2 imprinting pathway. Clin. Transl. Oncol. 16(4), 410–417 (2014).
  Medline CASGoogle Scholar
• 12 Taniguchi T, Schofield AE, Scarlett JL, Morison IM, Sullivan MJ, Reeve AE. Altered specificity of IGF2 promoter imprinting during fetal development and onset of Wilms tumor. Oncogene 11(4), 751–756 (1995).
  Medline CASGoogle Scholar
• 13 Ogawa T, Ogawa K, Shiga K et al. Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma. European Arch. Oto-Rhino-Laryngol. 267(10), 1599–1606 (2010).
  MedlineGoogle Scholar
• 14 Chen CL, IP SM, Cheng D, Wong LC, Hy N. Loss of imprinting of the IGF-II and H19 genes in epithelial ovarian cancer. Clin. Cancer Res. 6, 474–479 (2000).
  Medline CASGoogle Scholar
• 15 Tao R, Hu S, Wang S et al. Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma. Carcinogenesis 36(10), 1136–1143 (2015).
  Medline CASGoogle Scholar
• 16 Qiu H, Liu Q, Li J et al. Analysis of the association of HOTAIR single nucleotide polymorphism (rs920778) and risk of cervical cancer. APMIS 124(7), 567–573 (2016).
  Medline CASGoogle Scholar
• 17 Du M, Wang W, Jin H et al. The association analysis of lncRNA HOTAIR genetic variants and gastric cancer risk in a Chinese population. Oncotarget 6(31), 31255–31262 (2015).
  MedlineGoogle Scholar
• 18 Li S, Hua Y, Jin J et al. Association of genetic variants in lncRNA H19 with risk of colorectal cancer in a Chinese population. Oncotarget 7(18), 25470–25477 (2016).
  MedlineGoogle Scholar
• 19 Yang C, Tang R, Ma X et al. Tag SNPs in long non-coding RNA H19 contribute to susceptibility to gastric cancer in the Chinese Han population. Oncotarget 6(17), 15311–15320 (2015).
  MedlineGoogle Scholar
• 20 Haddad SA, Lunetta KL, Ruiz-Narvaez EA et al. Hormone-related pathways and risk of breast cancer subtypes in African American women. Breast Cancer Res. Treatment 154(1), 145–154 (2015).
  Medline CASGoogle Scholar
• 21 Yoon AJ, Zavras AI, Chen MK, Lin CW, Yang SF. Association between Gly1619ARG polymorphism of IGF2R domain 11 (rs629849) and advanced stage of oral cancer. Med. Oncol. 29(2), 682–685 (2012).
  Medline CASGoogle Scholar
• 22 Hoyo C, Murphy SK, Schildkraut JM et al. IGF2R genetic variants, circulating IGF2 concentrations and colon cancer risk in African Americans and Whites. Dis. Markers 32(2), 133–141 (2012).
  Medline CASGoogle Scholar
• 23 Couvert P, Carrié A, Tezenas Du Montcel S et al. Insulin-like growth factor 2 gene methylation in peripheral blood mononuclear cells of patients with hepatitis C related cirrhosis or hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol. 36(4), 345–351 (2012).
  Medline CASGoogle Scholar
• 24 Gong W-J, Yin J-Y, Li X-P et al. Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumor Biol. 37(6), 8349–8358 (2016).
  Medline CASGoogle Scholar
• 25 Murrell A, Heeson S, Cooper WN et al. An association between variants in the IGF2 gene and Beckwith–Wiedemann syndrome: interaction between genotype and epigenotype. Hum. Mol. Genet. 13(2), 247–255 (2004).
  Medline CASGoogle Scholar
• 26 Petry CJ, Seear RV, Wingate DL et al. Associations between paternally transmitted fetal IGF2 variants and maternal circulating glucose concentrations in pregnancy. Diabetes 60(11), 3090–3096 (2011).
  Medline CASGoogle Scholar
• 27 Liu Y, Tang Y, Ye D et al. Impact of abnormal DNA methylation of imprinted loci on human spontaneous abortion. Reprod. Sci. 25(1), 131–139 (2017).
  MedlineGoogle Scholar
• 28 Dong Y, Li J, Han F et al. High IGF2 expression is associated with poor clinical outcome in human ovarian cancer. Oncol. Rep. 34(2), 936–942 (2015).
  Medline CASGoogle Scholar
• 29 Huang GS, Brouwer-Visser J, Ramirez MJ et al. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin. Cancer Res. 16(11), 2999–3010 (2010).
  Medline CASGoogle Scholar
• 30 Brouwer-Visser J, Lee J, McCullagh K, Cossio MJ, Wang Y, Huang GS. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer. PLoS ONE 9(6), e100165 (2014).
  MedlineGoogle Scholar
• 31 Pearce CL, Doherty JA, Van Den Berg DJ et al. Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Hum. Mol. Genet. 20(11), 2263–2272 (2011).
  Medline CASGoogle Scholar
• 32 Zhu QN, Wang G, Guo Y et al. LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget 8(54), 91990–92003 (2017).
  MedlineGoogle Scholar
• 33 Matouk IJ, Raveh E, Abu-Lail R et al. Oncofetal H19 RNA promotes tumor metastasis. Biochim. Biophys. Acta 1843(7), 1414–1426 (2014).
  Medline CASGoogle Scholar
• 34 Zheng ZG, Xu H, Suo SS et al. The essential role of H19 contributing to cisplatin resistance by regulating glutathione metabolism in high-grade serous ovarian cancer. Sci Rep 6, 26093 (2016).
  Medline CASGoogle Scholar
• 35 Francis-Thickpenny KM, Richardson DM, Van Ee CC et al. Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma. Br. J. Cancer 85(5), 687–691 (2001).
  Medline CASGoogle Scholar
• 36 Jones S, Wang TL, Shih Ie M et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (New York) 330(6001), 228–231 (2010).
  CASGoogle Scholar
• 37 Sato N, Tsunoda H, Nishida M et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 60(24), 7052–7056 (2000).
  Medline CASGoogle Scholar
• 38 Wiegand KC, Lee AF, Al-Agha OM et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J. Pathol. 224(3), 328–333 (2011).
  Medline CASGoogle Scholar